Last reviewed · How we verify
Shionogi & Co. — Portfolio Competitive Intelligence Brief
4507.T (TSE)
5 marketed
0 filed
7 Phase 3
9 Phase 2
12 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Fetroja | CEFIDEROCOL | marketed | Cephalosporin Antibacterial | Infectious Disease | 2019-01-01 | |
| Ulesfia | BENZYL ALCOHOL | marketed | Pediculicide [EPC] | Dermatology | 2009-01-01 | |
| Doribax | DORIPENEM | marketed | Penem Antibacterial | Infectious Disease | 2007-01-01 | |
| Keflex | cefalexin | marketed | Cephalosporin Antibacterial | Solute carrier family 15 member 2 | Metabolic | 1971-01-01 |
| Cuvposa | GLYCOPYRRONIUM BROMIDE | marketed | Anticholinergic | Muscarinic acetylcholine receptor M1 | Metabolic | 1961-01-01 |
| Nonhormonal vaginal lubricant | Nonhormonal vaginal lubricant | phase 3 | Women's Health | |||
| S-268019-b | S-268019-b | phase 3 | 5-HT4 receptor partial agonist | 5-HT4 receptor | Gastroenterology | |
| Ospemifene (Dose 1) | Ospemifene (Dose 1) | phase 3 | Selective estrogen receptor modulator (SERM) | Estrogen receptor (ER-α and ER-β) | Women's Health / Gynecology | |
| S-217622 | S-217622 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes | |
| Placebo to Baloxavir Marboxil | Placebo to Baloxavir Marboxil | phase 3 | Cap-dependent endonuclease inhibitor | Influenza virus PA endonuclease (cap-dependent endonuclease) | Infectious Disease / Virology | |
| Oral Glycopyrrolate Liquid | Oral Glycopyrrolate Liquid | phase 3 | Anticholinergic | Muscarinic acetylcholine receptor | Respiratory | |
| Pravafen | Pravafen | phase 3 | Other |
Therapeutic area mix
- Infectious Disease · 2
- Metabolic · 2
- Gastroenterology · 1
- Infectious Disease / Virology · 1
- Other · 1
- Respiratory · 1
- Women's Health · 1
- Dermatology · 1
- Women's Health / Gynecology · 1
- Diabetes · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Cuvposa · 11278683 · US
- — Cuvposa · 8479730 · US
- — Cuvposa · 8182838 · US
- — Cuvposa · 9265900 · US
- — Cuvposa · 10940110 · US
- — Cuvposa · 8324266 · US
- — Cuvposa · 10716753 · US
- — Cuvposa · 9463161 · US
- — Cuvposa · 9415009 · US
- — Cuvposa · 8808713 · US
- — Cuvposa · 8703806 · US
- — Cuvposa · 9789270 · US
- — Cuvposa · 8815258 · US
- — Cuvposa · 9168556 · US
- — Cuvposa · 9604018 · US
- — Cuvposa · 10376661 · US
- — Cuvposa · 10688518 · US
- — Cuvposa · 10744277 · US
- — Cuvposa · 11331442 · US
- — Cuvposa · 11110054 · US
- — Cuvposa · 10456354 · US
Competitive overlap (companies sharing drug classes)
- AstraZeneca · 2 shared drug classes
- Shandong Suncadia Medicine Co., Ltd. · 2 shared drug classes
- Ain Shams University · 2 shared drug classes
- Astellas Pharma Inc · 2 shared drug classes
- AbbVie · 2 shared drug classes
- Sanofi · 2 shared drug classes
- · 2 shared drug classes
- Abbott · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shionogi & Co.:
- Shionogi & Co. pipeline updates — RSS
- Shionogi & Co. pipeline updates — Atom
- Shionogi & Co. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shionogi & Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shionogi. Accessed 2026-06-10.